Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Editorial Volume 6 Issue 4

A "Trojan Horse" Against Metastatic Cancer

Adrian P Hunis*

Clinical Oncology, Assistant Professor of Internal Medicine (UBA), Professor of Oncology (Universidad Maimónides), Argentina

*Corresponding Author: Adrian P Hunis, Clinical Oncology, Assistant Professor of Internal Medicine (UBA), Professor of Oncology (Universidad Maimónides), Argentina.

Received: June 15, 2022; Published: July 01, 2022

The fight against cancer has advanced exponentially in recent years. This has allowed the development of safer, less invasive and more effective treatments against those types that were more resistant to existing therapies.

References

Citation

Citation: Adrian P Hunis. “A "Trojan Horse" Against Metastatic Cancer" Acta Scientific Cancer Biology 6.4 (2022): 28-29.

Copyright

Copyright: © 2022 Adrian P Hunis. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US